Valuation: Daxor Corporation

Market Cap 6.18Cr 5.4Cr 4.98Cr 4.58Cr 8.68Cr 594.35Cr 8.83Cr 59Cr 23Cr 290.5Cr 23Cr 23Cr 1TCr P/E 2026 *
-50.5x
P/E 2027 * -353x
Enterprise Value 6.18Cr 5.4Cr 4.98Cr 4.58Cr 8.68Cr 594.35Cr 8.83Cr 59Cr 23Cr 290.5Cr 23Cr 23Cr 1TCr EV / Sales 2026 *
5.19x
EV / Sales 2027 * 2.97x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 week+1.05%
Current month+2.96%
1 month+9.62%
3 months+12.41%
6 months-22.63%
Current year-28.14%
1 week 10.11
Extreme 10.1101
11.19
1 month 9.37
Extreme 9.3666
11.19
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2013
Director of Finance/CFO 69 28/09/2018
Chief Tech/Sci/R&D Officer - 05/06/2024
Director TitleAgeSince
Director/Board Member 91 01/01/1989
Chairman 56 14/02/2017
Director/Board Member 70 22/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
-0.47%+1.05%+11.58%+8.72% 6.18Cr
-1.39%-2.93%+17.81%+98.36% 1.45TCr
-2.83%-6.25%+41.14%+112.13% 1.17TCr
+2.12%+3.41%-3.76%+35.60% 918.31Cr
+0.46%-1.59%-12.91%-12.63% 755.12Cr
-1.89%-4.36%+27.32%+110.44% 740.45Cr
-1.83%-1.27%+16.64%+60.48% 657.06Cr
+0.77%+2.44%+13.44%+27.71% 482.7Cr
+0.14%+1.51%+14.18%+9.01% 416.39Cr
-0.29%+0.66% - - 382.7Cr
Average -0.52%+0.34%+13.94%+49.98% 774.82Cr
Weighted average by Cap. -0.75%-0.12%+15.83%+66.05%

Financials

2026 *2027 *
Net sales 1.19Cr 1.04Cr 95.98L 88.23L 1.67Cr 114.5Cr 1.7Cr 11Cr 4.5Cr 56Cr 4.47Cr 4.37Cr 192.9Cr 2.08Cr 1.82Cr 1.68Cr 1.54Cr 2.92Cr 200.14Cr 2.97Cr 20Cr 7.86Cr 98Cr 7.81Cr 7.64Cr 337.17Cr
Net income -12L -10.49L -10L -9L -16.86L -12Cr -17.15L -1.16Cr -45.34L -5.64Cr -45.06L -44.08L -19Cr -2L -2L -2L -1L -3L -1.92Cr -3L -19.26L -8L -94.06L -8L -7L -3.24Cr
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
15/26/15 $10.60 -0.47% 1,817
14/26/14 $10.65 +5.34% 1,398
13/26/13 $10.11 -3.99% 378
10/26/10 $10.53 +4.15% 228
09/26/09 $10.11 -3.62% 759
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.60USD
Average target price
22.50USD
Spread / Average Target
+112.26%

Quarterly revenue - Rate of surprise